Home | Emory University

Infectious Diseases Clinical Research Consortium (IDCRC)

Infectious Diseases Clinical Research Consortium

Slide 1:
Slide 2:
Slide 3:
Slide 4:

The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.

Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine

Nine IDCRC sites enrolled participants in the the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273. An independent data and safety monitoring board overseeing the trial reported that the candidate was safe and well-tolerated and noted a vaccine efficacy rate of 94.5%.

NIH News

COVID-19 Vaccine Appears Well-Tolerated and Effective in Developing Antibodies in Small Study of Older Adults

COVID-19 Prevention Network

The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.

More about the CoVPN

COVID-19 Prevention Network launches two research studies evaluating monoclonal antibodies

About

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

IDCRC Active & Completed Studies

SUPPORT OF CLINICAL RESEARCH FOR 2019 NOVEL CORONAVIRUS (SARS-COV-2) & DISEASE (COVID-19)

The novel coronavirus 2019-nCoV, SARS-CoV-2, pandemic continues to expand and the IDCRC is working with NIAID to conduct clinical research into the treatment and prevention of infections (COVID-19) caused by this virus. What we know about COVID-19 and SARS-CoV-2 is constantly changing. To stay up-to-date on the most current information about how the epidemic is impacting the world, we recommend that you visit the following websites for reliable and accurate information.

View Resources

VTEU COVID-19 Trials

Warp Speed chief visits IDCRC & VTEU, urges participation in COVID vaccine trials

Operation Warp Speed's Chief Science Advisor visited Emory University and urged Americans to continue enrolling in ongoing COVID-19 vaccine trials. Emory IDCRC sites enrolled 103 participants out of 1062, more than any other site in the world.

Investigational COVID-19 Vaccine Well-Tolerated and Generates Immune Response in Older Adults

A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. New England Journal of Medicine

Emory begins advanced stage clinical trial for another COVID-19 vaccine

A portion of the sites are part of the NIAID-supported COVID-19 Prevention Network (CoVPN), a collaborative of four existing clinical research networks, including the Infectious Diseases Clinical Research Consortium based at Emory.

Remdesivir for the Treatment of COVID-19 - Final Report

The NIAID-sponsored, Infectious Diseases Clinical Research Consortium (IDCRC) and the nation’s Vaccine Trials and Evaluation Units (VTEUs) enrolled a quarter of all patients in this international study.